Impact of baseline cardiovascular risk on the outcomes of intensive blood pressure intervention: a post hoc analysis of the China rural hypertension control project

Guozhe Sun,Chang Wang,Ning Ye,Chuning Shi,Nanxiang Ouyang,Lixia Qiao,Guangxiao Li,Linlin Zhang,Yao Yu,Zhi Li,Ying Zhou,Zihan Chen,Shu Zhang,Pengyu Zhang,Danxi Geng,Wei Miao,Songyue Liu,Yingxian Sun

DOI: https://doi.org/10.1186/s12916-024-03494-w

IF: 9.3

2024-06-23

BMC Medicine

Abstract:The 2018/2023 ESC/ESH Guidelines underlined a gap how baseline cardiovascular disease (CVD) risk predicted blood pressure (BP) lowering benefits. Further, 2017 ACC/AHA Guideline and 2021 WHO Guideline recommended implementation studies about intensive BP control. Now, to bridge these guideline gaps, we conducted a post hoc analysis to validate whether the baseline CVD risk influences the effectiveness of the intensive BP control strategy, which was designed by China Rural Hypertension Control Project (CRHCP).

medicine, general & internal

What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating the impact of baseline cardiovascular disease (CVD) risk on the effectiveness of intensive blood pressure control strategies. Specifically, the study aims to verify whether intensive blood pressure control can effectively reduce the incidence of major cardiovascular events at different baseline CVD risk levels and to explore the safety and applicability of this intervention.

### Background and Issues
1. **Hypertension and Cardiovascular Disease**:
- Hypertension is one of the most important risk factors for cardiovascular disease, with substantial evidence supporting this.
- Recent studies suggest that considering both CVD risk and blood pressure levels together can more effectively guide antihypertensive treatment and reduce adverse events.

2. **Limitations of Existing Guidelines**:
- The 2021 WHO guidelines recommend that for hypertensive patients with high CVD risk, the target systolic pressure should be below 130 mmHg.
- The 2017 ACC/AHA guidelines recommend that for hypertensive adults with known CVD or a 10-year ASCVD risk ≥10%, the blood pressure target should be below 130/80 mmHg.
- However, these guidelines mainly focus on high CVD risk populations when setting blood pressure targets, with insufficient recommendations for low to moderate risk populations.
- The 2018 ESC/ESH guidelines directly pointed out the evidence gap regarding "what baseline CVD risk levels can predict treatment effects?"
- The 2023 ESH guidelines also emphasized the lack of evidence on blood pressure thresholds and targets in low to moderate risk individuals.

3. **Importance of the Study**:
- In optimizing blood pressure management, it is essential to consider not only the effectiveness of blood pressure reduction strategies in reducing major cardiovascular events and all-cause mortality but also to rigorously assess potential harms.
- Particularly in intensive blood pressure reduction strategies, the balance between treatment benefits and adverse reactions is crucial.
- Previous studies like the SPRINT and ACCORD trials partially covered high CVD risk populations, but the effects of intensive blood pressure control in low to moderate risk populations remain uncertain.

### Research Objectives
- **Hypothesis Verification**: Through a retrospective analysis of the China Rural Hypertension Control Project (CRHCP), explore the effects and safety of intensive blood pressure control strategies across different baseline CVD risk strata.
- **Specific Goals**:
- Compare the incidence of major cardiovascular events between the intensive blood pressure control group and the usual care group across different baseline CVD risk strata.
- Assess the absolute benefits of intensive blood pressure control strategies in different risk strata.
- Explore the safety of intensive blood pressure control strategies, particularly the occurrence of adverse events.

### Methods
- **Data Source**: CRHCP trial data.
- **Participant Screening**: Exclude participants with a history of CVD, those over 80 years old, or those with incomplete data.
- **Stratification and Random Grouping**: Participants are divided into four quartiles based on the estimated 10-year baseline CVD risk, with participants within each quartile randomly assigned to either the intensive blood pressure control group or the usual care group.
- **Intervention**: The target blood pressure for the intensive blood pressure control group is <130/80 mmHg, implemented by trained non-physician community health workers using a multifaceted treatment strategy.
- **Primary Outcomes**: Major cardiovascular events, including myocardial infarction, stroke, heart failure hospitalization, or CVD death.

### Results
- **Main Findings**:
- The incidence of major cardiovascular events in the intensive blood pressure control group was significantly lower than in the usual care group across all baseline CVD risk strata.
- Absolute risk reduction (ARR) increased with higher baseline CVD risk, with the highest ARR observed in the fourth quartile (high-risk group).
- Intensive blood pressure control strategies did not increase the risk of serious adverse events.
- **Safety Assessment**:
- The incidence of asymptomatic hypotension increased in the intensive blood pressure control group in higher risk strata, but there was no significant difference in symptomatic hypotension.
- Other adverse events such as electrolyte abnormalities, falls, syncope, and renal function impairment showed no significant differences between the two groups.

### Discussion
- **Significance of the Study**:
- This study fills the evidence gap in existing guidelines for low to moderate CVD risk populations, confirming the effectiveness and safety of intensive blood pressure control strategies across different risk strata.
- For clinical practice...